Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR34 | Q9UPC5 | 9/20 | 0.71 |
| ▸ | HTRA1 | Q92743 | 3/20 | 0.57 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.57 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | CDC25B | P30305 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18228910 | 1.00 | GPR34 (0.71) | GPR34HTRA1GPR132PTPN2PTPN1 | |
| SCHEMBL21959502 | 0.90 | GPR34 (0.68) | GPR34HTRA1PTPN2PTPN1CDC25B | |
| SCHEMBL18228657 | 0.90 | GPR34 (0.68) | GPR34HTRA1PTPN2PTPN1CDC25B | |
| SCHEMBL10727176 | 0.88 | GPR34 (0.73) | GPR34GPR132MEN1KMT2A | |
| SCHEMBL7296506 | 0.88 | GPR34 (0.73) | GPR34GPR132MEN1KMT2A | |
| SCHEMBL7970010 | 0.88 | GPR34 (0.73) | GPR34GPR132MEN1KMT2A | |
| SCHEMBL27154066 | 0.87 | GPR34 (0.83) | GPR34PTPN2PTPN1CDC25BMEN1 | |
| SCHEMBL10724456 | 0.87 | GPR34 (0.83) | GPR34PTPN2PTPN1CDC25BMEN1 | |
| SCHEMBL21959107 | 0.85 | GPR34 (0.65) | GPR34HTRA1PTPN2PTPN1CDC25B | |
| SCHEMBL18228648 | 0.85 | GPR34 (0.65) | GPR34HTRA1PTPN2PTPN1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531653-B | Novel difluoroketoamide derivatives | 豪夫迈·罗氏有限公司 | 2021-10-19 | — | — | CN | disclosed |
| EP-3294718-B1 | NEW DIFLUOROKETAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-10428108-B2 | Difluoroketamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428108-B2 | Difluoroketamide derivatives | PRMT9, CDK9, FLT3 | GPR34 1793/4885HTRA1 4586/4885GPR132 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.